Cargando…
RETRACTED ARTICLE: Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy
Platinum drugs are the frontline therapy in many carcinomas, including high-grade serous ovarian cancers. Clinically, high-grade serous carcinomas have an apparent complete response to carboplatin, but tumors invariably recur and response to platinum drugs diminishes over time. Standard of care proh...
Autores principales: | La, V., Fujikawa, R., Janzen, D. M., Nunez, M., Bainvoll, L., Hwang, L., Faull, K., Lawson, G., Memarzadeh, S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5551455/ https://www.ncbi.nlm.nih.gov/pubmed/28804784 http://dx.doi.org/10.1038/s41698-017-0008-z |
Ejemplares similares
-
Retraction Note: Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy
por: La, V., et al.
Publicado: (2021) -
Editorial Expression of Concern: birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy
por: La, V., et al.
Publicado: (2018) -
cIAP1/2 are involved in the radiosensitizing effect of birinapant on NSCLC cell line in vitro
por: Sun, Hao, et al.
Publicado: (2021) -
Efficacy of birinapant in combination with carboplatin in targeting platinum-resistant epithelial ovarian cancers
por: Singh, Tanya, et al.
Publicado: (2022) -
SMAC mimetic birinapant inhibits hepatocellular carcinoma growth by activating the cIAP1/TRAF3 signaling pathway
por: Ding, Jun, et al.
Publicado: (2020)